Fig. 1: Comparative analysis of D + E and decitabine regimens in elderly AML/MDS patients.

a Swimmer plot illustrating overall responses: This plot delineates the onset and duration of responses in patients treated with each regimen. An arrow indicates patients who are still alive. b Overall survival (left) and event-free survival (right) were analyzed in all patients treated with either the decitabine regimen (labeled “Decitabine”) or the combination of decitabine and etoposide (labeled “D + E”). c Focused survival analysis in responding patients: Overall survival (left) and event-free survival (right) were evaluated specifically in patients who showed a response (CR, CRi, or HI) to either the “Decitabine” or “D + E” regimen. d, e Enhanced exome sequencing and response results in D + E group (d) and decitabine group (e). This panel presents the sequencing outcomes for patients who experienced varying degrees of response, and the frequencies of responses and non-responses are correlated with specific mutations identified through sequencing. f Survival analysis in D + E Group (TP53 mutant vs. wild-type): This analysis compares overall survival and event-free survival between patients with TP53 mutations and those with wild-type TP53 within the D + E treatment. g Comparative survival in TP53 mutant patients (decitabine vs. D + E): This analysis contrasts the outcomes in TP53 mutant patients treated with decitabine alone and the D + E regimen.